Protection from chemical-induced acute lung injury
View Patent ↗Methods are provided herein for treating an individual having a disease, disorder or condition affecting the lungs, wherein said disease, disorder, or condition of the lung is an acute lung injury. In specific embodiments, the acute lung injury is chemical induced acute lung injury (CIALI). In some embodiments, the methods are provided for treating or protecting a subject from chemical induced acute lung injury that include administering to the subject a therapeutically effective amount of a phosphatase located on chromosome 10 (PTEN) inhibitor such as N(9,10-dioxo-9,10-di-hydrophenanthren-2-yl)pivalamide (SF1670). In some embodiments, the method products a subject from CAILI or reduces CAILI that results from a subsequent exposure to a chemical that induces chemical induced acute lung injury.
1. A method of protecting a subject from chemical induced acute lung injury, comprising administering to a subject exposed to a chemical, wherein the chemical is acrolein, chlorine or phosgene, a therapeutically effective amount of N(9,10-dioxo-9,10-di-hydrophenanthren-2-yl) pivalamide (SF1670), thereby protecting the subject from the chemical induced acute lung injury.
2. The method of claim 1 , wherein the chemical is chlorine.
3. The method of claim 1 , wherein the subject is human.
4. The method of claim 1 , wherein protecting the subject from chemical induced acute lung injury comprises reducing a symptom of the chemical induced acute lung injury.
5. The method of claim 1 , wherein the N(9,10-dioxo-9,10-di-hydrophenanthren-2-yl) pivalamide (SF1670) is administered about 5 to about 60 minutes following exposure to the chemical that induces chemical induced acute lung injury.
6. The method of claim 5 , wherein the N(9,10-dioxo-9,10-di-hydrophenanthren-2-yl) pivalamide (SF1670) is administered about 30 minutes following exposure to the chemical.
7. The method of claim 1 , wherein the chemical is phosgene.
8. The method of claim 1 , comprising detecting an improvement in one or more symptoms of lung injury by one or more of spirometry, peak flow meter, detection of O 2 and/or CO 2 levels in the blood, radiography, CT scanning, magnetic resonance imaging, bronchoscopy, or broncheoalveolar lavage.
9. The method of claim 1 , wherein the N(9,10-dioxo-9,10-di-hydrophenanthren-2-yl) pivalamide (SF1670) is administered systemically.
10. The method of claim 1 , wherein the N(9,10-dioxo-9,10-di-hydrophenanthren-2-yl) pivalamide (SF1670) is administered by inhalation.
11. The method of claim 1 , wherein the N(9,10-dioxo-9,10-di-hydrophenanthren-2-yl) pivalamide (SF1670) promotes epithelial wound repair.
12. The method of claim 1 , wherein the subject is a healthy subject.
13. The method of claim 1 , further comprising administering to the subject an effective amount of an anti-inflammatory agent, a bronchodilator, an expectorant, a leukotriene antagonist, a leukotriene formation inhibitor, an anti-oxidant, or a mast cell stabilizer.
14. The method of claim 1 , further comprising administering to the subject a therapeutically effective amount of an antioxidant.
15. The method of claim 1 , wherein the chemical is acrolein.